담즙산과 대사질환
Bile Acids and the Metabolic Disorders
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Bile acids are major constituents of bile and known to help absorb dietary fat and fat-soluble vitamins in the gastrointestinal tract. In the past few decades, many studies have shown that bile acids not only play a role in fat digestion but also function as broadrange of signal transduction hormones by binding to various receptors present in cell membranes or nuclei. Bile acid receptors aredistributed in a wide range of organs and tissues in the human body. They perform multitudes of physiological functions withcomplex mechanisms. When bile acids bind to their receptors, they regulate fat and glucose metabolism in a tissue-specific way. In addition, bile acids are shown to inhibit inflammation and fibrosis in the liver. Considering the roles of bile acids as metabolicregulators, bile acids and their receptors can be very attractive targets in treating metabolic disorders. In the future, if roles of bileacids and their receptors are further clarified, they will be the novel target of drugs in the treatment of various metabolic diseases.
Abstract
Bile acids are major constituents of bile and known to help absorb dietary fat and fat-soluble vitamins in the gastrointestinal tract. In the past few decades, many studies have shown that bile acids not only play a role in fat digestion but also function as broadrange of signal transduction hormones by binding to various receptors present in cell membranes or nuclei. Bile acid receptors aredistributed in a wide range of organs and tissues in the human body. They perform multitudes of physiological functions withcomplex mechanisms. When bile acids bind to their receptors, they regulate fat and glucose metabolism in a tissue-specific way. In addition, bile acids are shown to inhibit inflammation and fibrosis in the liver. Considering the roles of bile acids as metabolicregulators, bile acids and their receptors can be very attractive targets in treating metabolic disorders. In the future, if roles of bileacids and their receptors are further clarified, they will be the novel target of drugs in the treatment of various metabolic diseases.
참고문헌 (40)
- Esteller A, "Physiology of bile secretion", World J Gastroenterol, 14(37), pp.5641~5649 (2008)
- Houten SM, "Endocrine functions of bile acids", Embo J, 25(7), pp.1419~1425 (2006)
- Zhu C, "Bile acids in regulation of inflammation and immunity: friend or foe?", Clin Exp Rheumatol, 34(4Suppl 98), pp.25~31 (2016)
- Lefebvre P, "Role of bile acids and bile acid receptors in metabolic regulation", Physiol Rev, 89(1), pp.147~191 (2009)
- Handelsman Y, "Role of bile acid sequestrants in the treatment of type 2diabetes", Diabetes Care, 34(Suppl 2), pp.S244~S250 (2011)
- Neuschwander-Tetri BA, "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial", Lancet, 385(9972), pp.956~965 (2015)
- "Study of the effects of obeticholic acid on farnesoid X receptor expression in jejunum and on gut microbiota in morbidly obese patients and healthy volunteers"[URL]
- Aguiar Vallim TQ, "Pleiotropic roles of bile acids in metabolism", Cell Metab, 17(5), pp.657~669 (2013)
- Han CY, "Update on FXR biology: promising therapeutic target?", Int J Mol Sci, 19(7), pp.2069~ (2018)
- Chiang JY, "Bile acids : regulation of synthesis", J Lipid Res, 50(10), pp.1955~1966 (2009)
- Lazaridis KN, "Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’", J Hepatol, 35(1), pp.134~146 (2001)
- Monte MJ, "Bile acids: chemistry, physiology, and pathophysiology", World J Gastroenterol, 15(7), pp.804~816 (2009)
- Afroze S, "The physiological roles of secretin and its receptor", Ann Transl Med, 1(3), pp.29~ (2013)
- Li T, "Bile acid signaling in metabolic disease and drug therapy", Pharmacol Rev, 66(4), pp.948~983 (2014)
- Thomas C, "Targeting bile-acid signalling for metabolic diseases", Nat Rev Drug Discov, 7(8), pp.678~693 (2008)
- Makishima M, "Vitamin D receptor as an intestinal bile acid sensor", Science, 296(5571), pp.1313~1316 (2002)
- Matsubara T, "FXR signaling in the enterohepatic system", Mol Cell Endocrinol, 368(1-2), pp.17~29 (2013)
- Claudel T, "The farnesoid X receptor : a molecular link between bile acid and lipid and glucose metabolism", Arterioscler Thromb Vasc Biol, 25(10), pp.2020~2030 (2005)
- Zhang Y, "Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation", J Biol Chem, 278(1), pp.104~110 (2003)
- Thomas C, "TGR5-mediated mile acid sensing controls glucose homeostasis", Cell Metab, 10(3), pp.167~177 (2009)
- Kawamata Y, "A G protein-coupled receptor responsive to bile acids", J Biol Chem, 278(11), pp.9435~9440 (2003)
- Massotte, Dominique, "The G protein-coupled receptors handbook, 16", pp.3~4 (2005), Humana Press
- Forman BM, "Identification of a nuclear receptor that is activated by farnesol metabolites", Cell, 81(5), pp.687~693 (1995)
- Chiang JY, "Farnesoid X receptor responds to bile acids and represses cholesterol 7α-hydroxylase gene(CYP7A1)transcription", J Biol Chem, 275(15), pp.10918~10924 (2000)
- Kim I, "Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine", J Lipid Res, 48(12), pp.2664~2672 (2007)
- Pineda Torra I, "Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor", Mol Endocrinol, 17(2), pp.259~272 (2003)
- Cyphert HA, "Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21", J Biol Chem, 287(30), pp.25123~25138 (2012)
- Kharitonenkov A, "FGF-21 as a novel metabolic regulator", J Clin Invest, 115(6), pp.1627~1635 (2005)
- Claudel T, "Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease", Biochim Biophys Acta, 1812(8), pp.867~878 (2011)
- Nevens F, "A placebo-controlled trial of obeticholic acid in primary biliary cholangitis", N Engl J Med, 375(7), pp.631~643 (2016)
- Lackey DE, "Regulation of metabolism by the innate immune system", Nat Rev Endocrinol, 12(1), pp.15~28 (2016)
- Chavez-Talavera O, "Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease", Am J Gastroenterol, 152(7), pp.1679~1694 (2017)
- The asianpacific perspective: redefining obesity and its treatment, "World health organization international obesity task force", WHO Western Pacific Region, 17~18 (2000)
- 박종현, "체질량지수와 유의한 상관성을 갖는 질환들의 이환율을 이용한 한국인의 체질량지수 변별점 측정: ROC 곡선을 이용하여", Journal of Obesity & Metabolic Syndrome, 20(1), pp.36~43 (2011), 대한비만학회
- Hamilton MT, "The role of low energy expenditure and sitting on obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease", Diabetes, 56(11), pp.2655~2667 (2007)
- Watanabe M, "Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation", Nature, 439(7075), pp.484~489 (2006)
- Drucker DJ, "The incretin system : glucagon-like peptide-1receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes", Lancet, 368(9548), pp.1696~1705 (2006)
- Astrup A, "Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study", Lancet, 374(9701), pp.1606~1616 (2009)
- Molinaro A, "Role of bile acids in metabolic control", Trends Endocrinol Metab, 29(1), pp.31~41 (2018)
- Kars M, "Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women", Diabetes, 59(8), pp.1899~1905 (2010)